The acute administration of synthetic human GLP-1 to obese patients with and without T2DM reduced circulating interleukin-6 in only those with T2DM, without affecting levels of leptin, adiponectin or obestatin [16]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.